Solutions

Online Inquiry

Your Name *

Phone Number *

E-mail Address *

Services Interested *

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Vibrio Vulnificus Infection

It is crucial to design effective treatment modalities and vaccines at the earliest due to the notable economic burden Vibrio vulnificus infections impose on the aquaculture industry. Our company prides itself on offering comprehensive vaccine and therapy development services tailored specifically for Vibrio vulnificus infections.

Overview of Vibrio Vulnificus Infection

A gram-negative bacterial pathogen Vibrio vulnificus is an aquatic microbe which is highly pathogenic to coastal populations where seafood is an important source of nutrition. This pathogen can undergo a very rapid course on infection to cause severe septicemia and has high mortality, especially in people with liver disease type conditions. The infection is contracted by the consumption of raw as well as improperly cooked seafood and by having open wounds in the infected seawater.

Reported Vibrio vulnificus cases in the United States from 1988 to 2010. Fig.1 Vibrio vulnificus cases reported in the United States, 1988-2010. (Baker-Austin, C., et al., 2018)

Bivalent Inactivated Vaccines

A promising bivalent inactivated vaccine is reported to have been successful in turbot, a kind of fish in the genus Scophthalmus. The vaccine, which contains Montanide ISA 763 AVG as an adjuvant, increases the survival rate and elicits both types of immune response, cellular and humoral. Its efficacy was demonstrated through an RPS of 77% for Aeromonas salmonicida and Vibrio vulnificus challenge.

Multi-Epitope Peptide Vaccines

Regarding humans, immunoinformatics has advanced for the development of a new multi-epitope peptide vaccine. This method provides a bioinformatics approach to identify promising epitope vaccine candidates, among which the vibC and flgL proteins were found to have a very high affinity to the main, HLA allele in humans. The immunogenic design of the constructed vaccine is anticipated to mount a strong immune response, through B and T cell epitopes, in the selected individual.

Therapeutics Development for Vibrio Vulnificus Infection

Antibiotic Studies

There have been studies analyzing the effectiveness of antibiotics such as ceftriaxone, cefepime, doxycycline, and ciprofloxacin on cellular and livin animal models. The use of combination therapies has provided better results than the empirical singular use as they have dramatically improved survival chances of the infected mice and reduced the bacteria proliferation.

Iron Sequestration Therapies

Considering V. vulnificus's attachment to iron for cell reproduction, efforts to further treatment of this species were suggested concentrating on iron deprivation. It would be ideal to restrict the growth of this bacterium by targeting it increasing the capturing affinity of transferrin by certain strains.

Our Services

Given our in-depth research capabilities and know-how, we further seek to provide innovative solutions whilst offering comprehensive Vibrio vulnificus infection vaccine and therapeutic development services to international pharmaceutical companies.

Vaccine Development

Therapeutic Development

Disease Models

Iron-Dextran-Treated Mouse Models: Mice are injected intraperitoneally (i.p.) with iron dextran to increase susceptibility to V. vulnificus infection
Zebrafish (Danio rerio) Models: Immersion, intraperitoneal injection

Our preclinical research services involve the rigorous evaluation of vaccine candidates and therapeutic agents. We utilize state-of-the-art facilities and methodologies to assess the safety, efficacy, and immunogenicity of these products. If you are interested in our services, please feel free to contact us.

References

Baker-Austin, Craig, and James D. Oliver. "Vibrio vulnificus: new insights into a deadly opportunistic pathogen." Environmental microbiology 20.2 (2018): 423-430.
Wang, Jieyi, et al. "Clinical features and treatment outcomes of Vibrio vulnificus infection in the coastal city of Ningbo, China." Frontiers in Microbiology 14 (2023): 1220526.
Xiu, Yunji, et al. "Evaluation of Immune Protection of a Bivalent Inactivated Vaccine against Aeromonas salmonicida and Vibrio vulnificus in Turbot." Fishes 9.4 (2024): 131.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.